Pharvaris (NASDAQ:PHVS) CEO Sells $66,972.24 in Stock

Pharvaris N.V. (NASDAQ:PHVS) CEO Berndt Modig sold 2,292 shares of the stock in a transaction dated Monday, May 18th. The shares were sold at an average price of $29.22, for a total transaction of $66,972.24. Following the completion of the sale, the chief executive officer directly owned 137,500 shares in the company, valued at approximately $4,017,750. The trade was a 1.64% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Berndt Modig also recently made the following trade(s):

• On Thursday, April 16th, Berndt Modig sold 2,292 shares of Pharvaris stock. The shares were sold at an average price of $28.60, for a total transaction of $65,551.20.
• On Thursday, April 9th, Berndt Modig sold 23,333 shares of Pharvaris stock. The shares were sold at an average price of $27.74, for a total transaction of $647,257.42.

Pharvaris Trading Down 2.8%

Shares of NASDAQ PHVS opened at $29.68 on Friday. The stock has a market cap of $1.94 billion, a price-to-earnings ratio of -9.33 and a beta of -2.34. Pharvaris N.V. has a 52 week low of $15.46 and a 52 week high of $33.33. The company’s 50-day moving average price is $28.46 and its 200 day moving average price is $26.81.

Pharvaris (NASDAQ:PHVS) last issued its quarterly earnings data on Tuesday, May 12th. The company reported ($0.70) EPS for the quarter, beating analysts’ consensus estimates of ($0.82) by $0.12. As a group, research analysts expect that Pharvaris N.V. will post -3.25 earnings per share for the current year.

Institutional Investors Weigh In On Pharvaris

Several large investors have recently made changes to their positions in the business. California State Teachers Retirement System increased its position in shares of Pharvaris by 2.2% in the fourth quarter. California State Teachers Retirement System now owns 23,982 shares of the company’s stock worth $666,000 after acquiring an additional 520 shares in the last quarter. JPMorgan Chase & Co. increased its position in shares of Pharvaris by 30.6% in the second quarter. JPMorgan Chase & Co. now owns 3,342 shares of the company’s stock worth $59,000 after acquiring an additional 783 shares in the last quarter. GF Fund Management CO. LTD. acquired a new stake in shares of Pharvaris in the fourth quarter worth $35,000. Public Employees Retirement System of Ohio increased its position in shares of Pharvaris by 20.7% in the fourth quarter. Public Employees Retirement System of Ohio now owns 7,569 shares of the company’s stock worth $210,000 after acquiring an additional 1,300 shares in the last quarter. Finally, Legal & General Group Plc increased its position in shares of Pharvaris by 17.2% in the second quarter. Legal & General Group Plc now owns 11,550 shares of the company’s stock worth $203,000 after acquiring an additional 1,695 shares in the last quarter.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Pharvaris in a report on Tuesday, April 21st. Wedbush upped their target price on shares of Pharvaris from $41.00 to $42.00 and gave the company an “outperform” rating in a report on Tuesday, April 7th. Royal Bank Of Canada reduced their target price on shares of Pharvaris from $52.00 to $51.00 and set an “outperform” rating on the stock in a report on Monday, April 6th. Citizens Jmp reduced their target price on shares of Pharvaris from $75.00 to $74.00 and set a “market outperform” rating on the stock in a report on Wednesday, May 13th. Finally, Wall Street Zen upgraded shares of Pharvaris from a “strong sell” rating to a “sell” rating in a report on Saturday, May 16th. Ten equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $49.18.

About Pharvaris

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.